A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.Leukemia · 2018
   Guideline
2. The Ongoing Challenges of Managing Cytopenic Myelofibrosis in 2025: The Emergence of Non-JAK Inhibitor Therapies.Blood and lymphatic cancer : targets and therapy · 2025
   Review
3. How I manage anemia related to myelofibrosis and its treatment regimens.Annals of hematology · 2023
   Review
4. Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors.Current hematologic malignancy reports · 2022
   Review
5. Defining disease modification in myelofibrosis in the era of targeted therapy.Cancer · 2022
   Review
6. JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis.Journal of immunotherapy and precision oncology · 2021
   Review
7. The Rationale for Immunotherapy in Myeloproliferative Neoplasms.Current hematologic malignancy reports · 2019
   Review
8. Rethinking clinical trial endpoints in myelodysplastic syndromes.Leukemia · 2019
   Review
9. Standard care and investigational drugs in the treatment of myelofibrosis.Drugs in context · 2019
   Review
10. Management of Myelofibrosis-Related Cytopenias.Current hematologic malignancy reports · 2018
    Review
11. Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis.Current hematologic malignancy reports · 2018
    Review
12. Responses to pomalidomide and placebo in myelofibrosis-related anaemia.Leukemia · 2017
    Article

Corrections and comments

• Erratum for
  A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.2017

Authors and funding

17 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.